{"id":20507,"date":"2023-10-27T09:23:16","date_gmt":"2023-10-27T09:23:16","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20507"},"modified":"2023-10-27T11:52:33","modified_gmt":"2023-10-27T11:52:33","slug":"emmes-acquires-vaxtrials","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/emmes-acquires-vaxtrials\/","title":{"rendered":"Emmes acquires VaxTRIALS"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Emmes acquires VaxTRIALS<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS\u2019 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.<\/h3>\n

<\/p>\n

\u201cToday\u2019s clinical trials are both more complex and more global in nature than ever before,\u201d said Sastry Chilukuri, Emmes Executive Chairman. \u201cCombining VaxTRIALS\u2019 depth of expertise in Latin America and Emmes\u2019 strengths, particularly in technology, biostatistics and data management, will give clients an unmatched partnership experience in conducting their clinical trials.\u201d<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Peter Ronco, Emmes Chief Executive Officer, added: \u201cVaxTRIALS is a highly complementary match for Emmes. It extends our global reach from our current base in North America, Europe and Asia to Latin America, one of the fastest growing regions for clinical trials due to its large, diverse patient population and high-quality clinical research sites. VaxTRIALS adds a number of new biopharmaceutical and public-private partnership clients and further strengthens one of our largest research therapeutic areas: vaccines and infectious diseases.\u201d<\/p>\n

VaxTRIALS\u2019 vaccine-related clinical trials have been conducted in 11 Latin American countries, as well as the Philippines. Their trials have covered diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio and COVID-19.<\/p>\n

\u201cAnother benefit for Emmes,\u201d said Ronco, \u201cis that we\u2019ll be able to take advantage of VaxTRIALS\u2019 established network in Latin America to reach clinical trial participants in our other core therapeutic areas, including rare and paediatric diseases, cell and gene therapy, and ophthalmology.\u201d<\/p>\n

Dr Jos\u00e9 Jimeno, VaxTRIALS CEO commented: \u201cBoth our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research. I am proud that we have made both people and cultural development a priority, including hiring and developing employees who care deeply about making a difference in public health.<\/p>\n

\u201cI\u2019m also excited to incorporate Emmes\u2019 technology expertise, as well as legacy and depth in biostatistical analysis and data management, for the benefit of our clients throughout Latin America,\u201d he added. \u201cEmmes\u2019 Advantage eClinical data management platform, with benefits including improving data quality, easing oversight of clinical trial operations, and reducing trial timelines and costs, can be extremely
\nhelpful to our customers.\u201d<\/p>\n<\/div><\/section>
\n